The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
2023 · Cancers · 8 citations
https://doi.org/10.3390/cancers15184587
S
Sofia Verkhovskaia
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
40
Papers
365
Citations
7
h-index
5
i10-index
Sofia Verkhovskaia is an academic researcher from Istituto Dermopatico dell'Immacolata. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Lung Cancer Treatments and Mutations & Melanoma and MAPK Pathways. The author has an h-index of 7, co-authored 34 publications.
ORCID: 0009-0008-2599-807XPapers by this author
worksWeekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience
2024 · BMC Cancer · 6 citations
https://doi.org/10.1186/s12885-024-12961-9
15P The ROME trial: Personalized target therapy and immunotherapy in the breast cancer subgroup
2025 · ESMO Open · 1 citations
https://doi.org/10.1016/j.esmoop.2025.104569
14P Comprehensive genomic profiling to guide personalized targeted and immunotherapy in gastrointestinal tumors: Subgroup analysis of the ROME trial
2025 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2025.05.026
BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
2015 · Journal of Translational Medicine · 0 citations
https://doi.org/10.1186/1479-5876-13-s1-p8
95O Atezolizumab plus ipatasertib shows promise in extending survival for patients with PI3K/AKT/PTEN-altered advanced solid tumors: An exploratory analysis of the ROME trial
2025 · ESMO Open · 0 citations
https://doi.org/10.1016/j.esmoop.2025.104256
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat